Treatment of mood disorders with divalproex sodium: Efficacy, tolerability and safety;O papel do divalproato de sódio no tratamento dos transtornos do humor: Eficácia, tolerabilidade e segurança

Revista de Psiquiatria Clinica

Volumn 29, Issue 1, 2002, Pages 42-53

  Tung, Teng Chei ^a   Moreno, Ricardo Alberto ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Divalproex; Efficacy; Safety; Tolerability; Valproic acid

Indexed keywords

ANTICONVULSIVE AGENT; VALPROATE SEMISODIUM;

AFFECTIVE NEUROSIS; DRUG ABSORPTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPHORIA; GASTROINTESTINAL TOXICITY; HUMAN; LIVER TOXICITY; MANIA; MANIC DEPRESSIVE PSYCHOSIS; NEUROLOGIC DISEASE; PANCREATITIS; REVIEW;

EID: 0036223181     PISSN: 01016083     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (89)

1. Valproic acid and trombocytopenia in children: A case-controlled retrospective study
2. Valproate-associated pancreatitis
3. Maintenance treatment in bipolar disorder
4. Valproic acid: A review of its pharmacology and therapeutic potencial in indications other than epilepsy
5. Drug-induced acute pancreatites: A critical review
6. Pancreatite aguda associada ao uso de divalproex de sódio
7. Valproate, carnitine metabolism and biochemical indicators of liver function
8. Individualized patient assessment in the treatment of epilepsy with sodium valproate
9. Efficacy of divalproex vs. lithium and placebo in the treatment of mania
10. A randomized, placebo-controlled 12-month trial of divalproex and lithium in the treatment of outpatients with bipolar I disorder
11. Maintenance therapies for classic and other forms of bipolar disorder
12. Valproate in the treatment of acute bipolar affective episodes complicated by substance abuse: A pilot study
13. Delayed toxicity following ingestion of enteric-coated divalproex sodium (Epival)
14. Valproic acid hepatic fatalities III: U.S. experience since 1986
15. Spectrum of efficacy of valproate in 55 patients with rapid-cycling bipolar disorder
16. Predictors of valproate response in bipolar rapid cycling
17. Lithium and anticonvulsants in the treatment of bipolar disorder
18. Valproate and carbamazepine comedication changes hepatic enzyme activities in sera of epileptic children
19. Mood stabilizers during breastfeeding: A review
20. Valproate robustly enhances AP-1 mediated gene-expression
21. Efficacy of lithium vs. valproate in the treatment of mania in the elderly: A retrospective study
22. Valproic acid a reappraisal of its pharmacological properties and clinical efficacy in epilepsy
23. Comprehensive review of the psychiatric uses of valproate
24. Thrombocytopenia secondary to high valproate levels in children with epilepsy
25. Sodium valproate increases pupillary responsiveness to a cholinergic agonist in responders with mania
26. Weight gain associated with valproate in childhood
27. Side effects of valproate
28. Valproic acid hepatic fatalities II: U.S. experience since 1984
29. Valproic acid hepatic fatalities: A retrospective review
30. Recurrent acute pancreatitis associated with valproic acid use for mood stabilization
31. The expert consensus guidelines for treating depression in bipolar disorder
32. Mood stabilizer combinations: A review of safety and efficacy
33. A double-blind comparison of valproate and lithium in the treatment of acute mania
34. Clinical valproate toxicity induced by acetylsalicylic acid
35. Long-term uses of valproate in primary psychiatric disorders
36. Side effects of sodium valproate in monotherapy controlled by plasma levels: A study in 88 pediatric patients
37. Safety and tolerability of oral loading divalproex sodium in acutely manic bipolar patients
38. Selenium, zinc and copper changes with valproic acid: Possible relation to drug side effects
39. Valproate and carbamazepine increase prefrontal dopamine release by 5HT1 a receptor activation
40. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy
41. Emerging clinical applications of divalproex
42. A review of randomized, controlled clinical trials in acute mania
43. Sodium valproate as an antidepressant
44. Effect size of lithium, divalproex sodium, and carbamazepine in children and adolescents with bipolar disorder
45. The efficacy and tolerability of divalproex sodium in elderly demented patients with behavioral disturbances
46. Drug interaction with valproic acid
47. Effects of subchronic treatment with valproate on 1-5-HTP-induced cortisol responses in mania: Evidence for increased central serotonergic neurotransmission
48. Hematological manifestations of long-term valproate therapy
49. Clinical correlates of valproate augmentation in refractory bipolar disorder
50. Valproate
51. Variability and clinical relevance of the interaction between sodium valproate and carbamazepine in epileptic patients
52. Valproate for rapid-cycling unipolar affective disorder
53. Pharmacotherapy of depression and mixed states in bipolar disorder
54. Valproate as an adjunct to neuroleptic medication for the treatment of acute episodes of mania: A prospective, double-blind, placebo-controlled, multicenter study
55. Valproic acid-induced neural tube defects in mouse and human: Aspects of chirality, alternative drug development, pharmacokinetics and possible mechanism
56. The use of intravenous valproate in acute mania
57. Chronic lithium and sodium valproate both decrease the concentration of myo-inositol and increase the concentration of inositol monophosphates in rat brain
58. Valproate induced hyperammonemia in the psychiatric setting: 2 Cases
59. Valproate induced lupus-like syndrome
60. GABA and mood disorders: A brief review and hypothesis
61. Sleep disorders and depression with atypical features. Response to valproate
62. Multiorgan system failure caused by valproic acid toxicity
63. Serum valproate levels in 6 breastfeeding mother-infant pairs
64. An open trial of valproate for agitation in geriatric neuropsychiatric disorders
65. Valproic acid amide as a prophylactic agent in affective and schizoaffective disorders
66. Misdiagnosis of pancreatitis during valproate treatment in gastro-oesofageal reflux
67. Phenomenology and treatment of agitation
68. Adverse effects of valproate
69. Valproate treatment and the risk of hyperandrogenism and polycystic ovaries
70. A pilot study of lithium carbonate plus divalproex sodium for the continuation and maintenance treatment of patients with bipolar I disorder
71. Lithium plus valproate as maintenance polypharmacy for patients with bipolar I disorder: A review
72. A potential drug interaction between fluoxetine and valproic acid
73. Lithium-associated cognitive and functional deficits reduced by a switch to divalproex sodium: A case series
74. Metabolite profile in patients on high-dose valproate monotherapy
75. Depression during mania. Treatment response to lithium or divalproex
76. Mania: Differential effects of previous depressive and manic episodes on response to treatment
77. O uso de anticoulsivantes no transtorno afetivo bipolar
78. Simultaneous "in series" hemodialisys and hemoperfusion in the management of valproic acid overdose
79. The adverse effect profile and safety of divalproex
80. Blood dyscrasias with carbamazepine and valproate: A pharmacoepidemiological study of 2228 patients at risk
81. Dispensing information
82. Carbamazepine and valproate monotherapy: Feasibility, relative safety and efficacy, and therapeutic drug monitoring in manic disorder
83. Platelet count and function in children receiving sodium valproate
84. Medikamentös induzierte pankreatitiden: Erfahrungen der Schweizerischen Arzbeimittell-Nebenwirkungszentrale (SANZ)
85. Drug induced pancreatitis
86. Serum levels of valproate and carbamazepine in breastfeeding mother-infant pairs
87. Routine laboratory monitoring for serious adverse effects of antiepileptic medications: The controversy
88. Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for the treatment of patients with bipolar depression
89. The adverse effect profile and efficacy of divalproex sodium compared with valproic acid: A pharmacoepidemiological study